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Does a single Pseudomonas aeruginosa
isolation predict COPD mortality?
To the Editor:
Patients with chronic obstructive pulmonary disease (COPD) often suffer from acute exacerbations
(AECOPD) of their disease, which have a significant impact on their health status [1]. Evidence suggests
that ,50% of these exacerbations are attributable to bacteria [2]. Pseudomonas aeruginosa can cause
AECOPD and is associated with reduced survival in cystic fibrosis (CF) and bronchiectasis [3, 4]. Some
studies have found that the presence of P. aeruginosa is also associated with mortality in COPD, but these
findings have been based on patients hospitalised with exacerbations [5, 6] or those hospitalised with
multidrug-resistant organisms [7].
The impact of P. aeruginosa identified in sputum from COPD outpatients is less clear but is an important
issue for determining how aggressive strategies to attempt eradication should be. Therefore, we conducted a
nested case–control study to investigate whether the isolation of P. aeruginosa in the sputum of a general
COPD population was associated with long-term mortality.
We first identified all sputum specimen results from Royal Brompton Hospital (London, UK) microbiology
records between 2000 and 2012. These were cross-correlated with patients listed on our COPD research
audit database. The reason for obtaining a sputum culture was not recorded systematically, but included
repeated exacerbations and deterioration in symptom severity and/or clinical status, as well as opportunistic
collection from patients with chronic sputum production. The laboratory threshold for a culture to be
considered P. aeruginosa positive was 200 CFU?mL-1 (a semi-quantitative method). For patients with
repeated positive sputum cultures the date of the first culture was recorded. Demographic variables, lung
function measurements, gas transfer data, arterial blood gases and exacerbation frequency during the year
prior to entering the study were recorded for all patients.
All analyses were performed using the Predictive Analytics Software (version 18; SPSS Inc., Chicago, IL,
USA). Group comparisons were conducted utilising a t-test or the Chi-squared test as appropriate.
Proportional Cox hazard analysis was utilised to assess: 1) the impact of parameters that differed between
P. aeruginosa culture-positive and culture-negative groups and 2) the impact of antibiotic treatment on
mortality. The proportionality hazard assumption was tested using partial residual plots (Schoenberg
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residuals proportionality hazard test). The Kaplan–Meier survival curve with the Log rank comparison was
used to assess the impact of P. aeruginosa isolation on mortality and estimate the median survival of the
P. aeruginosa culture-positive and culture-negative groups. A p-value ,0.05 was considered significant.
The initial cohort consisted of 380 subjects (247 male and 133 female), with a mean¡SD age of
66.3¡10.3 years and a forced expiratory volume in 1 s (FEV1) of 36.7¡18.3 % predicted. 95 (25%)
patients from the initial population had at least one positive sputum culture for P. aeruginosa, while the rest
had either negative cultures or cultured bacteria other than P. aeruginosa. 66 P. aeruginosa culture-positive
patients from the initial cohort were matched to another 66 P. aeruginosa culture-negative patients for sex,
age and FEV1 % predicted.
Differences in demographics and clinical characteristics between the initial COPD cohort and the study
population, and P. aeruginosa culture-positive and culture-negative patients are presented in table 1.
Although the initial matching was done according to three baseline variables, the two final groups were
found to be similar in all recorded parameters of lung function (forced vital capacity, FEV1/forced vital
capacity, diffusing capacity of the lung for carbon monoxide, transfer coefficient of the lung for carbon
monoxide, total lung capacity, residual volume and residual volume/total lung capacity), as well as body
mass index and arterial oxygen tension. Arterial carbon dioxide tension (p50.018) and exacerbation rate
(p50.008) were higher in the P. aeruginosa culture-positive patients compared to the P. aeruginosa culture-
negative patients (table 1). However, proportional Cox hazard analysis, which was conducted separately for
each group, indicated that exacerbation rate had no impact on mortality (P. aeruginosa culture-positive:
hazard ratio 1.334 (95% CI 0.351–5.067), p50.672; P. aeruginosa culture-negative: hazard ratio 2.161 (95%
CI 0.576–8.112), p50.253). The results were similar for arterial carbon dioxide tension (P. aeruginosa culture-
positive: hazard ratio 1.134 (95% CI 0.758–1.697), p50.539; P. aeruginosa culture-negative: hazard ratio 1.074
(95% CI 0.842–1.369), p50.572), indicating that it was not associated with survival.
Median (range) survival for the study population (n5132) was 81.2 (50.8–109.5) months. During this
period 51 (38.6%) patients died, of these 52.9% (n527) were P. aeruginosa culture-positive and 47.1%
(n524) were P. aeruginosa culture-negative. The Kaplan–Meier survival curve, using the Log rank
comparison, indicated that P. aeruginosa positive sputum culture was not associated with mortality in
this population. Median (range) survival for P. aeruginosa culture-positive patients was 80.1 (40.1–120.1)
months compared to 88.6 (52–125.3) months in the P. aeruginosa culture-negative patients (p50.49)
(fig. 1). Furthermore, no differences in survival as a function of the presence of Pseudomonas would
have been identified if the entire population of 380 had been analysed (data not shown).
TABLE 1 Baseline differences between the initial cohort and the study population, and the Pseudomonas aeruginosa culture-
positive and culture-negative groups
Initial cohort Study population p-value# P. aeruginosa culture-
positive group
P. aeruginosa culture-
negative group
p-value"
Subjects n 380 132 66 66
Age years 65.4¡10.9 68¡8.8 0.011 68¡8.8 68.3¡9 0.969
Sex %
Male 51.1 51.1 0.999
Female 47.4 47.4
BMI m?kg-2 24.7¡5.2 24¡6.3 0.257 23.6¡5.8 24.4¡6.8 0.497
FEV1 % predicted 38.6¡20.1 (9–81.1) 33.6¡14.7 (12.6–72.4) 0.008 33.4¡14.5 (12.6–72.4) 33.8¡14.9 (12.9–71) 0.882
FEV1/FVC % 40.6¡21.2 (13–69.8) 36.1¡16.8 (13.5–69.8) 0.029 35¡12.1 (14.1–69.8) 37.2¡20.7 (13.5–69.5) 0.456
DLCO % predicted 43.7¡18.1 40.8¡17.4 0.157 41.5¡18.2 40.1¡16.7 0.663
KCO % predicted 54.8¡21.6 54¡22.1 0.747 55.5¡21.8 52.5¡22.4 0.448
TLC % predicted 123.7¡19.6 122.7¡17 0.662 121.1¡18.1 124.5¡15.6 0.286
RV % predicted 205.1¡61.9 203.3¡53 0.780 206¡52.8 200.5¡53.6 0.569
RV/TLC 155.2¡32.7 157¡32.1 0.639 60.3¡9.8 59.4¡11.6 0.647
PaO2 kPa 9.5¡1.4 9.0¡1.5 0.014 9.1¡1.4 8.9¡1.8 0.440
PaCO2 kPa 5.3¡0.8 5.5¡1.1 0.116 5.3¡0.9 5.8¡1.4 0.018
Exacerbations per year 1.9¡0.7 2.1¡0.7 0.086 2.3¡0.7 1.9¡0.7 0.008
Data are presented as mean¡SD or mean¡SD (range), unless otherwise stated. Bold signifies statistical significance. BMI: body mass index; FEV1:
forced expiratory volume in 1 s; FVC: forced vital capacity; DLCO: diffusing capacity of the lung for carbon monoxide; KCO: transfer coefficient of the
lung for carbon monoxide; TLC: total lung capacity; RV: residual volume; PaO2: arterial oxygen tension; PaCO2: arterial carbon dioxide tension.
#: level of significance for comparison between the initial cohort and the study population; ": level of significance for comparison between the P.
aeruginosa culture-positive and culture-negative groups.
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A secondary analysis was also undertaken to identify whether Pseudomonas eradication treatment among P.
aeruginosa culture-positive patients had any impact on survival. Sputum samples were ordered on a clinical
basis and the decision of whether to attempt to eradicate Pseudomonas was at the discretion of the treating
physician. Out of 66 P. aeruginosa culture-positive patients, 34 (25.8%) did not receive any treatment while
32 (24.2%) were treated either with oral ciprofloxacin or appropriate intravenous antibiotics, depending
on resistance pattern. These two patient subgroups were similar regarding age, sex, body mass index,
pulmonary function testing variables and exacerbation rate (data not shown). Cox proportional hazard
analysis indicated that P. aeruginosa treatment was not associated with mortality (hazard ratio 1.452 (95%
CI 0.666–3.163), p50.348) among P. aeruginosa culture-positive patients.
This study indicates that a single isolate of P. aeruginosa in sputum from a general COPD population is
not associated with worse survival. Recently, three different patterns of P. aeruginosa infection in COPD
patients have been described: 1) short carriage and clearance of a P. aeruginosa strain; 2) acquisition of a
new strain associated with an AECOPD; and 3) persistence of P. aeruginosa colonisation with unknown
clinical significance [8]. Although the specific pattern of P. aeruginosa infection was not investigated in the
current study, our results indicate that even though a single positive P. aeruginosa sputum culture was
correlated with a higher exacerbation frequency, it was not associated with a worse long-term outcome in
COPD outpatients.
The results of our study may, to some extent, be limited by its retrospective design and by the relatively
small number of patients included, although a formal power estimation was not conducted. However, most
of the published studies in the field have used similar sample sizes to investigate the potential impact of P.
aeruginosa infection on COPD survival [2, 6, 9]. Another limitation is the lack of baseline data on exercise
capacity, dyspnoea severity and frequency of previous hospitalisations, all of which could have affected
mortality. Moreover, high-resolution computed tomography of the chest was not systematically conducted
in all patients so the prevalence of bronchiectasis, a factor which could have favoured P. aeruginosa
infection, could not be estimated; although it should be noted that our institution runs separate clinics for
patients known to have either CF or non-CF bronchiectasis. However, several of these prognostic factors [6, 7]
and imaging data [6, 7, 9] are also lacking in previously published studies that investigated the effect of P.
aeruginosa on COPD mortality. Furthermore, careful patient matching has controlled for most of the lung
function parameters that could affect mortality [10], so these negative results could not be attributed to a
selected patient subgroup.
In conclusion, this study indicated that a single P. aeruginosa sputum isolation is not a predictor of long-
term mortality in a general COPD outpatient population. Current clinical practice usually targets
P. aeruginosa eradication using radical treatment, after its isolation in the sputum of a COPD patient with
clinical deterioration or frequent exacerbations. Although eradicating Pseudomonas may be justified to
improve health status, patients and clinicians can, to an extent, be reassured by these data that if this is not
possible the impact on survival of a single P. aeruginosa isolation is not as significant as it is in CF [3] or
bronchiectasis [4]. Future prospective, case–control studies are needed in order to define exact criteria for
chronic P. aeruginosa infection in COPD patients and the best stratification criteria for a clinical trial of
P. aeruginosa eradication in COPD.
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FIGURE 1 Kaplan–Meier survival
curve for the Pseudomonas aeruginosa
culture-positive and P. aeruginosa
culture-negative groups. p50.49 for P.
aeruginosa culture-negative patients.
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Does traffic noise influence respiratory
mortality?
To the Editor:
Over the last decade, several studies have investigated the association between noise levels, primarily due to
road traffic in large cities, and pathologies not related to either traditional hearing impairments or sleep
disorders. These pathologies are mainly hypertension and cardiovascular, connective system and respiratory
diseases [1]. Their impact on public health has been assessed in time series studies, indicating a traffic noise
effect on both cardiovascular and respiratory hospital admissions rates similar to that attributed to air
pollutants [2]. In addition, a recent study has shown an association of noise levels with cardiovascular
mortality [3]. The description of the physiopathological mechanisms involved in this association reveal an
actual impact of current road traffic noise levels on health [1]. Others question this because of the high
correlation between traffic noise and air pollution [4], although a previous study in our setting showed an
independent association between noise and cardiovascular mortality from the effect of the primary chemical
air pollutants [5]. However, the effect of noise on respiratory mortality has not yet been investigated.
In this study, we examined the association between daily mortality due to respiratory causes (International
Classification of Diseases, 9th revision, codes 460–519) and daytime noise levels in the city of Madrid
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